Chapter I · 6 min read
The Map
The $19.4B US medspa market — sized by segment, scored across all 50 states + DC, and on pace for ~$30B by 2030.
The US medspa market is approaching $19.4 billion[1] in 2026.
By 2030, projections place it near ~$30 billion — compounding at about 10.8% a year.[5] For operators, the point is not just category growth. The upside is uneven by segment, state, and menu mix.
$19.4B
Market size (2026)
10.8%
Annual growth (CAGR)
US market on AmSpa methodology (locations × avg revenue); syndicated services-revenue models report a narrower base. AmSpa 2024 SOI, FotroMed, Apex Leaders.
Quick primer · What's a CAGR?
Compound Annual Growth Rate — the steady yearly rate that takes a market from its start value to its end value. An 11% CAGR means the market grows about 1.11× every year: like compound interest, but for market size.
Five segments, five different trajectories.
Injectables anchor the market at $8.1B[2] — but they aren't the fastest-growing line. Wellness & regenerative medicine is compounding at 18.5% a year, while body contouring is the one segment we expect to slow as GLP-1s reshape demand — a contrarian call you can trace in our GLP-1 signal in Chapter 2. Your menu mix, not the market's tailwind, decides which trajectory you ride.
$8.1B
Injectables
Botox, fillers, biostimulators
11.2% CAGR$4.1B
Lasers & Energy
Resurfacing, hair removal, IPL
8.5% CAGR$2.7B
Body Contouring
CoolSculpting, Emsculpt, lipo
6.2% CAGR$1.9B
Wellness & Regen
Peptides, PRP, GLP-1 adjacent
18.5% CAGR$2.5B
Skin Health
HydraFacial, peels, microneedling, PRP
2026 baselines from the US ~$19.4B medspa market (AmSpa method) × category share. Forward projections at stated CAGRs. Mirror model, anchored on Grand View injectables CAGR (11.2%) + the AmSpa market base. The $8.1B injectables figure is medspa-channel services revenue — roughly 2× the underlying $4.1B injectable product market (Grand View, 2024).
Some states are wide open. Others are already saturated.
We scored all 50 states + DC on demand intensity, supply density, and competitive pressure.
The top-opportunity markets outscore the most-saturated by nearly 30 points on our 100-point composite.[5] Where you operate — or where you expand — is the single biggest lever you control.
Highest opportunity
Most saturated
Composite score: demand × 0.4 + (100 − supply) × 0.4 + (100 − competition) × 0.2. Sources: AmSpa, Google Trends, Census.
Every road in this market leads back to injectables.
Forty-five percent of medspa revenue, 60–80% gross margins, and the highest repeat-visit frequency of any category.[1] No other segment ranks top on all three axes.
Why injectables dominate — three axes
No other segment ranks top on all three axes simultaneously.
45%
Revenue from injectables
$527
Average spend per visit
AmSpa 2024 State of the Industry, KMF / MediCreations profitability studies
Three readings of the same data.
- The category compounds ~11%/yr — appointments, not addressable market, are the constraint.
- Injectables are ~45% of revenue at 60–80% margins; defend that core before chasing new lines.
- Check your state's opportunity score before signing a second lease.
- ~$19.4B US medspa market (AmSpa method), heading toward ~$30B by 2030.
- ~10,500 locations today, heading to ~12,000 by 2027 — mostly independent, textbook platform math.
- Segment mix is the alpha: wellness/regen is the +18.5% tail.
- Top-opportunity states outscore the most-saturated by ~30 points on our composite.
- Where the menu bets — injectables vs body vs wellness — changes the trajectory.
- Body contouring is the soft spot as GLP-1s reshape demand.